<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35164631</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7658</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Expert opinion on investigational drugs</Title><ISOAbbreviation>Expert Opin Investig Drugs</ISOAbbreviation></Journal><ArticleTitle>Monoclonal antibody therapies in the management of SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>41</StartPage><EndPage>58</EndPage><MedlinePgn>41-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13543784.2022.2030310</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to prevent the emergence of resistant variants.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided. Finally, insights are offered into the potential benefits and challenges associated with the use of these agents.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">NAbs offer an effective, evidence-based therapeutic intervention during the early stages of SARS-CoV-2 infection when viral replication is the primary factor driving disease progression. As the pandemic progresses, appropriate use of NAbs will be important to minimize the risk of escape variants. Ultimately, the availability of effective treatments for COVID-19 will allow the establishment of treatment algorithms for minimizing the substantial rates of hospitalization, morbidity (including long COVID) and mortality currently associated with the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miguez-Rey</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Enfermedades Infecciosas, Hospital Universitario de A Coru&#xf1;a, A Coru&#xf1;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Dasom</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seungmin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Sangwook</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Celltrion Healthcare Co., Ltd., Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#x103;ndulescu</LastName><ForeName>Oana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases 'Prof. Dr. Matei Bal&#x219;', Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Investig Drugs</MedlineTA><NlmUniqueID>9434197</NlmUniqueID><ISSNLinking>1354-3784</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bamlanivimab and etesevimab</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">casirivimab and imdevimab</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">regdanvimab</Keyword><Keyword MajorTopicYN="N">sotrovimab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35164631</ArticleId><ArticleId IdType="pmc">PMC8862171</ArticleId><ArticleId IdType="doi">10.1080/13543784.2022.2030310</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . WHO Coronavirus (COVID-19) dashboard. 2021.  [cited 2021 May
23]; Available from: https://covid19.who.int/</Citation></Reference><Reference><Citation>Fried MW, Crawford JM, Mospan AR, et al. Patient characteristics and outcomes of 11,721 patients with coronavirus disease 2019 (COVID-19) hospitalized across the United States. Clin Infect Dis. 2021;72(10):e558&#x2013;e565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499515</ArticleId><ArticleId IdType="pubmed">32856034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim PS, Read SW, Fauci AS.. Therapy for early COVID-19: a critical need. JAMA. 2020;324(21):2149&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pubmed">33175121</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CH, Lu CH, Wong SH, et al. Update on antiviral strategies against COVID-19: unmet needs and prospects. Front Immunol. 2020;11:616595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892464</ArticleId><ArticleId IdType="pubmed">33613542</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . SARS-CoV-2 variants. 2020.  [cited 2021 May
23]; Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON305</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration . COVID-19 public health emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products. Guidance for industry and investigators. 2020 [cited 2021 May
26]; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-public-health-emergency-general-considerations-pre-ind-meeting-requests-covid-19-related</Citation></Reference><Reference><Citation>Department of Health and Human Services . Emergency use authorization declaration. A Notice by the Health and Human Services Department on 04/01/2020. 2020.  [cited 2021 May
26]; Available from: https://www.federalregister.gov/documents/2020/04/01/2020-06905/emergency-use-authorization-declaration</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration . Coronavirus Treatment Acceleration Program (CTAP). 2021.  [cited 2021 Oct
26]; Available from:
https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap</Citation></Reference><Reference><Citation>European Medicines Agency . COVID-19 treatments: research and development 2021 [cited 2021 Nov
8]; Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-research-development</Citation></Reference><Reference><Citation>European Medicines Agency . COVID-19 treatments: under evaluation. 2021.  [cited 2021 Nov
8]; Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-under-evaluation</Citation></Reference><Reference><Citation>European Medicines Agency . COVID-19 treatments: article 5 (3)reviews. 2021.  [cited 2021 Jul
10]; Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-article-53-reviews</Citation></Reference><Reference><Citation>European Commission . European Health Union: commission establishes portfolio of 10 most promising treatments for COVID-19. 2021.  [cited 2021 Dec
13]; Available from: https://cyprus.representation.ec.europa.eu/news/european-health-union-commission-establishes-portfolio-10-most-promising-treatments-covid-19-2021-10-22_en</Citation></Reference><Reference><Citation>European Commission . Questions and answers on the list of 10 candidate COVID-19 therapeutics. 2021.  [cited 2021 Dec
13]; Available from: https://ec.europa.eu/commission/presscorner/detail/en/qanda_21_5367</Citation></Reference><Reference><Citation>National Institutes of Health . Coronavirus disease 2019 (COVID-19) treatment guidelines. 2022.  [cited 2021 Jan
10]; Available from: https://www.covid19treatmentguidelines.nih.gov/</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7947358</ArticleId><ArticleId IdType="pubmed">33692120</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Therapeutics and COVID-19: living guideline. 2021 Jul 6 [cited 2021 Aug
31]; Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2</Citation><ArticleIdList><ArticleId IdType="pubmed">35917393</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Morgan R, Hirsch Shumaker A, et al. IDSA guidelines on the treatment and management of patients with COVID-19. Version 6.0.0. 2021 [cited 2022 Jan
25]; Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</Citation></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . Casirivimab plus imdevimab: Summary of Product Characteristics. 2021.  [cited 2021 Nov
30]; Available from: https://www.ema.europa.eu/en/documents/product-information/ronapreve-epar-product-information_en.pdf</Citation></Reference><Reference><Citation>ACTIV-3/TICO LY-CoV555 Study Group ; Lundgren JD, Grund B, Barkauskas CE, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384(10):905&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781100</ArticleId><ArticleId IdType="pubmed">33356051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646625</ArticleId><ArticleId IdType="pubmed">33113295</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilly E and Company . Fact sheet for health care providers. Emergency use authorization (EUA) of bamlanivimab and etesevimab. 2021.  [cited 2021 Jul
07]; Available from: https://www.fda.gov/media/145802/download</Citation></Reference><Reference><Citation>Regeneron . Fact sheet for health care providers. Emergency use authorization (EUA) of REGEN-COVTM (casivirimab and imdevimab). 2021 [cited 2021 Sep
16]; Available from: https://www.fda.gov/media/145611/download</Citation></Reference><Reference><Citation>European Medicines Agency . Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for unauthorised product Regkirona (regdanvimab). 2021.  [cited 2021 Jul
11]; Available from: https://www.ema.europa.eu/en/documents/referral/celltrion-use-regdanvimab-treatment-covid-19-article-53-procedure-conditions-use-conditions_en.pdf</Citation></Reference><Reference><Citation>European Medicines Agency . Regdanvimab: Summary of Product Characteristics. 2021.  [cited 2021 Nov
30]; Available from: https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf</Citation></Reference><Reference><Citation>Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383(19):1827&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377062</ArticleId><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307&#x2013;1316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489411</ArticleId><ArticleId IdType="pubmed">32876695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078880</ArticleId><ArticleId IdType="pubmed">33676589</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516650</ArticleId><ArticleId IdType="pubmed">34480127</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . Anakinra: Summary of Product Characteristics. 2021.  [cited 2022 Jan
4]; Available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf</Citation></Reference><Reference><Citation>Gordon CJ, Tchesnokov EP, Schinazi RF, et al. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297(1):100770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110631</ArticleId><ArticleId IdType="pubmed">33989635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Hill CS, Sarkar S, et al. beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224(3):415&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8136050</ArticleId><ArticleId IdType="pubmed">33961695</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabinger F, Stiller C, Schmitzova J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraco Y, Crofoot GE, Moncada PA, et al. Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid. 2021. Dec 16. DOI:10.1056/EVIDoa2100043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2100043</ArticleId><ArticleId IdType="pubmed">38319179</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2021;20211216. DOI:10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . EMA issues advice on use of Lagevrio (molnupiravir) for the treatment of COVID-19. 2021.  [cited 2021 Dec
13]; Available from: https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration . Fact sheet for healthcare providers: emergency use authorization for molnupiravir. 2021.  [cited 2022 Jan
4]; Available from: https://www.fda.gov/media/155054/download</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration . Fact sheet for healthcare providers: emergency use authorization for Paxlovid. 2021.  [cited 2022 Jan
4]; Available from: https://www.fda.gov/media/155050/download</Citation></Reference><Reference><Citation>Pfizer . Pfizer&#x2019;s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. 2021.  [cited 2021 Nov
8]; Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate</Citation></Reference><Reference><Citation>Atea Pharmaceuticals . Atea pharmaceuticals provides update and topline results for phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting. 2021.  [cited 2021 Nov
8]; Available from: https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2</Citation></Reference><Reference><Citation>Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia. Expert Opin Biol Ther. 2020;20(7):711&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196919</ArticleId><ArticleId IdType="pubmed">32329380</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7069465</ArticleId><ArticleId IdType="pubmed">32257537</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu R, Yan T, Feng Y, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms. Cell Res. 2021;20211026. DOI:10.1038/s41422-021-00573-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00573-y</ArticleId><ArticleId IdType="pmc">PMC8546390</ArticleId><ArticleId IdType="pubmed">34702946</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8046040</ArticleId><ArticleId IdType="pubmed">33400390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile P, Sterodimas A, Pizzicannella J, et al. Research progress on mesenchymal stem cells (MSCs), adipose-derived mesenchymal stem cells (AD-MSCs), drugs, and vaccines in inhibiting COVID-19 disease. Aging Dis. 2020;11(5):1191&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505274</ArticleId><ArticleId IdType="pubmed">33014532</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S, Nampoothiri M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch Med Res. 2020;51(6):482&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247499</ArticleId><ArticleId IdType="pubmed">32493627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100515</ArticleId><ArticleId IdType="pubmed">32221306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271&#x2013;280.e278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham J. Passive antibody therapy in COVID-19. Nat Rev Immunol. 2020;20(7):401&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290146</ArticleId><ArticleId IdType="pubmed">32533109</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol. 2021;18(10):2293&#x2013;2306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8424621</ArticleId><ArticleId IdType="pubmed">34497376</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez-Cruz NA, Garcia-Hernandez E, Espitia C, et al. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment. Microb Cell Fact. 2021;20(1):88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8061467</ArticleId><ArticleId IdType="pubmed">33888152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Chandele A, Sharma A. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. 2021;17(9):e1009885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8415613</ArticleId><ArticleId IdType="pubmed">34478455</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Adams AC, Hufford MM, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>Boechat JL, Chora I, Morais A, et al. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. Pulmonology. 2021;27(5):423&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040543</ArticleId><ArticleId IdType="pubmed">33867315</ArticleId></ArticleIdList></Reference><Reference><Citation>Khadke S, Ahmed N, Ahmed N, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Virol J. 2020;17(1):154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7558250</ArticleId><ArticleId IdType="pubmed">33059711</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Yuan M, Huang D, et al. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021;29(5):806&#x2013;818.e806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049401</ArticleId><ArticleId IdType="pubmed">33894127</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey M, Ozberk V, Eskandari S, et al. Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. Clin Transl Immunol. 2021;10(3):e1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7937407</ArticleId><ArticleId IdType="pubmed">33732459</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryadevara N, Shrihari S, Gilchuk P, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021;184(9):2316&#x2013;2331.e2315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962591</ArticleId><ArticleId IdType="pubmed">33773105</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BE, Brown-Augsburger PL, Corbett KS, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13(593):eabf1906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284311</ArticleId><ArticleId IdType="pubmed">33820835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MS, Nirula A, Mulligan MJ, et al. Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial. JAMA. 2021;326(1):46&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8176388</ArticleId><ArticleId IdType="pubmed">34081073</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385(13):1184&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362593</ArticleId><ArticleId IdType="pubmed">34347950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Li N, Wang G, et al. Tolerability, safety, pharmacokinetics, and immunogenicity of a novel SARS-CoV-2 neutralizing antibody, etesevimab in Chinese healthy adults: a randomized, double-blind, placebo-controlled, first-in-human phase 1 study. Antimicrob Agents Chemother. 2021;65(8):e0035021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284438</ArticleId><ArticleId IdType="pubmed">33972256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385(15):1382&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration . Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. 2021 [cited 2021 May
23]; Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab</Citation></Reference><Reference><Citation>Hoffmann M, Arora P, Gross R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384&#x2013;2393.e2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7980144</ArticleId><ArticleId IdType="pubmed">33794143</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Dingens AS, et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4):100255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19. 2021.  [cited 2021 May
26]; Available from: https://www.ema.europa.eu/en/news/ema-issues-advice-use-sotrovimab-vir-7831-treating-covid-19</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration . Emergency use authorization (EUA) for emergency use of sotrovimab. 2021 [cited 2021; Available from:
https://www.fda.gov/media/149534/download</Citation></Reference><Reference><Citation>National Institutes of Health . The COVID-19 Treatment Guidelines Panel&#x2019;s statement on bamlanivimab plus etesevimab for the treatment of mild to moderate COVID-19 in nonhospitalized patients. 2021.  [cited 2021 Sep
20]; Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-bamlanivimab-plus-etesevimab/</Citation></Reference><Reference><Citation>National Institutes of Health . The COVID-19 Treatment Guidelines Panel&#x2019;s statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. 2021.  [cited 2021 Dec
10]; Available from:
https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/</Citation></Reference><Reference><Citation>Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857396</ArticleId><ArticleId IdType="pubmed">33037066</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23):e81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration . Emergency use authorization (EUA) for emergency use of casirivimab and imdevimab. 2020 [cited 2021 May
26]; Available from: https://www.fda.gov/media/143891/download</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . SARS-CoV-2 variant classifications and definitions. 2021.  [cited 2021 Aug
31]; Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#</Citation></Reference><Reference><Citation>Kim C, Ryu DK, Lee J, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021;12(1):288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803729</ArticleId><ArticleId IdType="pubmed">33436577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Jang YR, Hong JH, et al. Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein: two randomized, placebo-controlled, phase i studies in healthy individuals and patients with mild SARS-CoV-2 infection. Clin Ther. 2021;43(10):1706&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380488</ArticleId><ArticleId IdType="pubmed">34551869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ison MG, Kim JY, Sandulescu O, et al. Therapeutic effect of regdanvimab in patients with mild to moderate COVID-19: day 28 results from a multicentre, randomised, controlled pivotal trial. Presented at: the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2021 Jul 9&#x2013;12; Vienna, Austria, Abstract 4650.</Citation></Reference><Reference><Citation>Syed YY. Regdanvimab: first approval. Drugs. 2021;81(18):2133&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8558754</ArticleId><ArticleId IdType="pubmed">34724174</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu DK, Song R, Kim M, et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem Biophys Res Commun. 2021;566:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180667</ArticleId><ArticleId IdType="pubmed">34119826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu DK, Kang B, Noh H, et al. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021;578:91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436435</ArticleId><ArticleId IdType="pubmed">34547629</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P, Kemp S, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Celltrion Healthcare [press release] . Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant. 2022.  [cited 2022 Jan
10]; Available from:
https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=556&amp;pagenumber=1&amp;keyword=&amp;keyword_type=</Citation></Reference><Reference><Citation>Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941&#x2013;1950.</Citation><ArticleIdList><ArticleId IdType="pubmed">34706189</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555956</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulse . COVID-19 treatment in Korea cost $57,562 per critically-ill, bill charged on state. 2020 [cited 2021 Jun
25]; Available from: https://pulsenews.co.kr/view.php?year=2020&amp;no=471089</Citation></Reference><Reference><Citation>Lee D, Choi B. Policies and innovations to battle Covid-19 - A case study of South Korea. Health Policy Technol. 2020;9(4):587&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7452839</ArticleId><ArticleId IdType="pubmed">32874856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinson D, Dang J, Shah A, et al. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811&#x2013;1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919620</ArticleId><ArticleId IdType="pubmed">33650025</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. The coronavirus is mutating - does it matter? Nature. 2020;585(7824):174&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">32901123</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey LB. RNA polymerase errors cause splicing defects and can be regulated by differential expression of RNA polymerase subunits. elife. 2015;4:e09945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4868539</ArticleId><ArticleId IdType="pubmed">26652005</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson F, Khan KS, Le TK, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79(5):710&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402271</ArticleId><ArticleId IdType="pubmed">32853546</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyano-Hern&#xe1;ez P, Reinosa R, Holgu&#xed;n &#xc1;. Evolution of SARS-CoV-2 envelope, membrane, nucleocapsid, and spike structural proteins from the beginning of the pandemic to September 2020: a global and regional approach by epidemiological week. Viruses. 2021;13(2):243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7913946</ArticleId><ArticleId IdType="pubmed">33557213</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante JA, Mitchell BM, Plante KS, et al. The variant gambit: COVID-19&#x2b9;s next move. Cell Host Microbe. 2021;29(4):508&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919536</ArticleId><ArticleId IdType="pubmed">33789086</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747004</ArticleId><ArticleId IdType="pubmed">33340022</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Tracking SARS-CoV-2 variants. 2021.  [cited 2021 Dec
14]; Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</Citation></Reference><Reference><Citation>Stanford University Coronavirus Antiviral &amp; Resistance Database . SARS-CoV-2 variants. 2021.  [cited 2021 Sep
16]; Available from: https://covdb.stanford.edu/page/mutation-viewer/</Citation></Reference><Reference><Citation>Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44&#x2013;57. e49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . Casirivimab and imdevimab: assessment report. 2021.  [cited 2021 Nov
30]; Available from: https://www.ema.europa.eu/en/documents/referral/regn-cov2-antibody-combination-casirivimab/imdevimab-covid19-article-53-procedure-assessment-report_en.pdf</Citation></Reference><Reference><Citation>European Medicines Agency . Bamlanivimab and etesevimab: assessment report. 2021.  [cited 2021 Nov
30]; Available from: https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-limited-antibody-combination-bamlanivimab/etesevimab-covid19-article-53-procedure-assessment-report_en.pdf</Citation></Reference><Reference><Citation>European Medicines Agency . Regdanvimab: assessment report. 2021.  [cited 2021 Nov
30]; Available from:
https://www.ema.europa.eu/en/documents/referral/regdanvimab-treatment-covid-19-celltrion-covid-19-article-53-procedure-assessment-report_en.pdf</Citation></Reference><Reference><Citation>European Medicines Agency . Sotrovimab: assessment report. 2021.  [cited 2021 Nov
30]; Available from:
https://www.ema.europa.eu/en/documents/referral/sotrovimab-also-known-vir-7831-gsk4182136-covid19-article-53-procedure-assessment-report_en.pdf</Citation></Reference><Reference><Citation>Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">32908214</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. &#x2018;Super-antibodies&#x2019; could curb COVID-19 and help avert future pandemics. Nat Biotechnol. 2021;39(7):783&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218965</ArticleId><ArticleId IdType="pubmed">34158667</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepenbrink MS, Park JG, Oladunni FS, et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep Med. 2021;2(3):100218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904445</ArticleId><ArticleId IdType="pubmed">33649747</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC COVID-19 Vaccine Breakthrough Case Investigations Team . COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158893</ArticleId><ArticleId IdType="pubmed">34043615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov M. Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021;20211221. DOI:10.1038/d41586-021-03829-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03829-0</ArticleId><ArticleId IdType="pubmed">34937889</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2021. Dec 23. DOI:10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Peltan ID, Beesley SJ, Webb BJ, et al. Evaluation of potential COVID-19 recurrence in patients with late repeat positive SARS-CoV-2 testing. PLoS One. 2021;16(5):e0251214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8096096</ArticleId><ArticleId IdType="pubmed">33945583</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey L, Beyrer C, Cohen MS, et al. SARS-CoV-2 variants in patients with immunosuppression. N Engl J Med. 2021;385(6):562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494465</ArticleId><ArticleId IdType="pubmed">34347959</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>